These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3905317)

  • 1. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine.
    Van Scoik KG; Johnson CA; Porter WR
    Drug Metab Rev; 1985; 16(1-2):157-74. PubMed ID: 3905317
    [No Abstract]   [Full Text] [Related]  

  • 2. The mode of action of immunosuppressive agents.
    Bach JF
    Front Biol; 1975; 41():1-374. PubMed ID: 1052787
    [No Abstract]   [Full Text] [Related]  

  • 3. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine.
    Gardiner SJ; Begg EJ; Barclay ML; Kirkpatrick CM
    Adverse Drug React Toxicol Rev; 2000 Dec; 19(4):293-312. PubMed ID: 11212460
    [No Abstract]   [Full Text] [Related]  

  • 6. Teratogen update: azathioprine and 6-mercaptopurine.
    Polifka JE; Friedman JM
    Teratology; 2002 May; 65(5):240-61. PubMed ID: 11967923
    [No Abstract]   [Full Text] [Related]  

  • 7. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatic oxidative metabolism on the immunosuppressive activities of 6-thiopurines.
    Abraham RT; Benson LM; Jardine I
    J Pharmacol Exp Ther; 1985 Sep; 234(3):670-6. PubMed ID: 3162017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines.
    Thomas CW; Myhre GM; Tschumper R; Sreekumar R; Jelinek D; McKean DJ; Lipsky JJ; Sandborn WJ; Egan LJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):537-45. PubMed ID: 15388785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
    Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical guide to the use of thiopurines in oral medicine.
    Hullah EA; Blaker PA; Marinaki AM; Escudier MP; Sanderson JD
    J Oral Pathol Med; 2015 Nov; 44(10):761-8. PubMed ID: 25529219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of xanthine oxidase in thiopurine metabolism: a case report.
    Wong DR; Derijks LJ; den Dulk MO; Gemmeke EH; Hooymans PM
    Ther Drug Monit; 2007 Dec; 29(6):845-8. PubMed ID: 18043486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunodepressants used in immune system pathology. I. Cyclosporin, cyclophosphane, azathioprine and mercaptopurine].
    Napolov IuK; Borisov KB
    Farmakol Toksikol; 1991; 54(4):80-7. PubMed ID: 1786839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the immunosuppressive effects of 6-mercaptopurine, azathioprine, cyclophosphamide and 036.5122 (Asta) on primary and secondary immune reactions in the mouse].
    Botzenhardt U; Lemmel EM
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1806-8. PubMed ID: 1030111
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assay.
    Pelin M; Genova E; Fusco L; Marisat M; Hofmann U; Favretto D; Lucafò M; Taddio A; Martelossi S; Ventura A; Stocco G; Schwab M; Decorti G
    Chem Biol Interact; 2017 Sep; 275():189-195. PubMed ID: 28811125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine.
    Sies C; Florkowski C; George P; Gearry R; Barclay M; Harraway J; Pike L; Walmsley T
    N Z Med J; 2005 Feb; 118(1210):U1324. PubMed ID: 15776100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine.
    Watanabe A; Hobara N; Nagashima H
    Acta Med Okayama; 1978 Jul; 32(3):173-9. PubMed ID: 29442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M; Herrlinger K; Schaeffeler E; Stange EF
    Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.